Imipénème ou méropénème, quel est le meilleur choix pour les infections à Pseudomonas aeruginosa ?
- 30 November 2003
- journal article
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 33 (11) , 579-583
- https://doi.org/10.1016/s0399-077x(03)00242-7
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997–2000)Diagnostic Microbiology and Infectious Disease, 2002
- Nosocomial Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa with a New bla IMP Allele, bla IMP-7Antimicrobial Agents and Chemotherapy, 2002
- MYSTIC program: summary of European data from 1997 to 2000Diagnostic Microbiology and Infectious Disease, 2001
- Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997–2000)Diagnostic Microbiology and Infectious Disease, 2001
- Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility testJournal of Antimicrobial Chemotherapy, 2001
- Antimicrobial Resistance in European Isolates of Pseudomonas aeruginosaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2000
- Carbapenemase-producing Pseudomonas aeruginosa in UKThe Lancet, 1998
- Acquired carbapenemasesJournal of Antimicrobial Chemotherapy, 1997
- Comparison of Antibacterial Activities of Meropenem and Six Other Antimicrobials Against Pseudomonas aeruginosa Isolates from North American Studies and Clinical TrialsClinical Infectious Diseases, 1997
- beta-Lactamases in laboratory and clinical resistanceClinical Microbiology Reviews, 1995